Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thomas Wicks

Thomas Wicks is chief strategy officer TrialScope. He has more than 20 years of experience with performance and content management solutions, specializing in applications for life sciences such as clinical trial disclosure, structured product labeling and submissions management. A frequent contributor to industry publications and speaker at industry events, he has been on focused on trial transparency since 2007.

Latest From Thomas Wicks

Robust Trial Transparency Strategy Boosts Patient Engagement

Most clinical trial sponsors view data disclosure as a mandate, maintaining regulatory compliance as a legal requirement. Study sponsors that realize the potential to repurpose this data, using a patient-first approach, turn transparency into a strategic advantage for engagement and recruitment efforts.

Clinical Trials Compliance

5 Steps To Mastering Global Clinical Trial Disclosure Compliance

Clinical trial disclosure compliance must include identification and documentation of registry requirements, key stakeholders, company policies, systems, and processes.

Clinical Trials Compliance

Clinical Data Transparency Is Big Challenge For Smaller Sponsors

Robust transparency, and perhaps even just compliance with evolving requirements of multiple regulators, requires commitment from the C-suite for companies of all sizes.

Clinical Trials Compliance

The Hidden Implications of Clinical Trial Disclosure Noncompliance

Potential fallout from noncompliance goes well beyond regulatory penalties; adherence has improved but less so for smaller companies.

United States Europe
See All